Primary liver cancer is among the most common fatal solid cancers, ranking as the fourth
most frequent cause of cancer-related mortality worldwide. Hepatocellular carcinoma (HCC)
is the most prevalent histological type of primary liver cancers, which accounts for up to 90%
of cases and is resistant to a large percentage of currently available anti-cancer drugs.
Amongst various therapeutic options, transarterial chemoembolization (TACE) is an efficient
option in patients with the intermediate stage of HCC. Commercially, different embolients …